Faecal microRNAs as a non-invasive tool in the diagnosis of colonic adenomas and colorectal cancer: A meta-analysis

[1]  T. Yau.  Precision treatment in colorectal cancer: Now and the future , 2019, JGH open : an open access journal of gastroenterology and hepatology.

[2]  J. Fleshman,et al.  MicroRNAs as potential liquid biopsy biomarkers in colorectal cancer: A systematic review. , 2018, Biochimica et biophysica acta. Reviews on cancer.

[3]  Fangfang Yang,et al.  MiR-92a promotes tumorigenesis of colorectal cancer, a transcriptomic and functional based study. , 2018, Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie.

[4]  Chang-ming Wang,et al.  LINC00312 represses proliferation and metastasis of colorectal cancer cells by regulation of miR‐21 , 2018, Journal of cellular and molecular medicine.

[5]  P. Malfertheiner,et al.  Circulating and Fecal microRNAs as Biomarkers for Inflammatory Bowel Diseases. , 2018, Inflammatory bowel diseases.

[6]  Zhengwei Leng,et al.  MiR-92a promotes stem cell-like properties by activating Wnt/β-catenin signaling in colorectal cancer , 2017, Oncotarget.

[7]  B. Han,et al.  MicroRNA-21 (Mir-21) Promotes Cell Growth and Invasion by Repressing Tumor Suppressor PTEN in Colorectal Cancer , 2017, Cellular Physiology and Biochemistry.

[8]  D. Ahlquist,et al.  Novel Approach to Fecal Occult Blood Testing by Assay of Erythrocyte-Specific microRNA Markers , 2017, Digestive Diseases and Sciences.

[9]  S. Kennedy,et al.  Investigation of miR-1202, miR-135a, and miR-16 in Major Depressive Disorder and Antidepressant Response , 2017, The international journal of neuropsychopharmacology.

[10]  H. Iinuma,et al.  Exosomal microRNA in plasma as a non-invasive biomarker for the recurrence of non-small cell lung cancer. , 2017, Oncology letters.

[11]  Reza Ghanbari,et al.  Investigation of MicroRNA-21 Expression Levels in Serum and Stool as a Potential Non-Invasive Biomarker for Diagnosis of Colorectal Cancer , 2017, Iranian biomedical journal.

[12]  Casey R. Vickstrom,et al.  PDE4 Inhibition Restores the Balance Between Excitation and Inhibition in VTA Dopamine Neurons Disrupted by Repeated In Vivo Cocaine Exposure , 2017, Neuropsychopharmacology.

[13]  Christopher D. Jensen,et al.  Fecal Immunochemical Test (FIT) for Colon Cancer Screening: Variable Performance with Ambient Temperature , 2016, The Journal of the American Board of Family Medicine.

[14]  D. Iliopoulos,et al.  Identification of Circulating MicroRNA Signatures in Crohn's Disease Using the Nanostring nCounter Technology , 2016, Inflammatory bowel diseases.

[15]  Xiao-yan Wu,et al.  Values of fecal microRNA-141, -17-3p and -92a-3p in the diagnosis and prognostic evaluation of colorectal cancer , 2016 .

[16]  R. Salehi,et al.  Locked nucleic acid inhibits miR-92a-3p in human colorectal cancer, induces apoptosis and inhibits cell proliferation , 2016, Cancer Gene Therapy.

[17]  Moustapha Kassem,et al.  microRNA expression profiling on individual breast cancer patients identifies novel panel of circulating microRNA for early detection , 2016, Scientific Reports.

[18]  Zhongmin Zhang,et al.  MicroRNA-92a Promotes Colorectal Cancer Cell Growth and Migration by Inhibiting KLF4. , 2016, Oncology research.

[19]  S. Wong,et al.  Systematic review with meta‐analysis: faecal occult blood tests show lower colorectal cancer detection rates in the proximal colon in colonoscopy‐verified diagnostic studies , 2016, Alimentary pharmacology & therapeutics.

[20]  M. Ma,et al.  Ubiquitin-specific protease 7 expression is a prognostic factor in epithelial ovarian cancer and correlates with lymph node metastasis , 2016, OncoTargets and therapy.

[21]  Yu-Sun Chang,et al.  MicroRNA-223 and microRNA-92a in stool and plasma samples act as complementary biomarkers to increase colorectal cancer detection , 2016, Oncotarget.

[22]  Jun Yu,et al.  microRNA-20a in human faeces as a non-invasive biomarker for colorectal cancer , 2015, Oncotarget.

[23]  Yao Liu,et al.  MicroRNA-21 and microRNA-146 a identification in stool and its clinical significance in colorectal neoplasms , 2016 .

[24]  Yili Yang,et al.  Fecal miR-29a and miR-224 as the noninvasive biomarkers for colorectal cancer. , 2016, Cancer biomarkers : section A of Disease markers.

[25]  M. Esteller,et al.  lncRNAs and microRNAs with a role in cancer development. , 2016, Biochimica et biophysica acta.

[26]  N. Laird,et al.  Meta-analysis in clinical trials revisited. , 2015, Contemporary clinical trials.

[27]  D. Iliopoulos,et al.  Assessment of Circulating MicroRNAs for the Diagnosis and Disease Activity Evaluation in Patients with Ulcerative Colitis by Using the Nanostring Technology , 2015, Inflammatory bowel diseases.

[28]  Xiaoyuan Xu,et al.  Differentially expressed genes and microRNAs in bladder carcinoma cell line 5637 and T24 detected by RNA sequencing. , 2015, International journal of clinical and experimental pathology.

[29]  D. Iliopoulos,et al.  MicroRNA214 Is Associated With Progression of Ulcerative Colitis, and Inhibition Reduces Development of Colitis and Colitis-Associated Cancer in Mice. , 2015, Gastroenterology.

[30]  I. Endo,et al.  Exosomal miRNAs from Peritoneum Lavage Fluid as Potential Prognostic Biomarkers of Peritoneal Metastasis in Gastric Cancer , 2015, PloS one.

[31]  A. Jemal,et al.  Global cancer statistics, 2012 , 2015, CA: a cancer journal for clinicians.

[32]  P. Wei,et al.  MiR-92a Promotes Cell Metastasis of Colorectal Cancer Through PTEN-Mediated PI3K/AKT Pathway , 2015, Annals of Surgical Oncology.

[33]  Hailong Xie,et al.  U6 is not a suitable endogenous control for the quantification of circulating microRNAs. , 2014, Biochemical and biophysical research communications.

[34]  F. Cameron,et al.  Inflammation and MiR-21 Pathways Functionally Interact to Downregulate PDCD4 in Colorectal Cancer , 2014, PloS one.

[35]  Yaou Zhang,et al.  MiR-194 Deregulation Contributes To Colorectal Carcinogenesis via Targeting AKT2 Pathway , 2014, Theranostics.

[36]  Jun Yu,et al.  microRNA-221 and microRNA-18a identification in stool as potential biomarkers for the non-invasive diagnosis of colorectal carcinoma , 2014, British Journal of Cancer.

[37]  E. Chan,et al.  Global fecal microRNA profiling in the identification of biomarkers for colorectal cancer screening among Asians. , 2014, Oncology reports.

[38]  Li-Ming Zhou,et al.  Correlation of over-expressions of miR-21 and Notch-1 in human colorectal cancer with clinical stages. , 2014, Life sciences.

[39]  P. Pavlidis,et al.  miR-1202: A Primate Specific and Brain Enriched miRNA Involved in Major Depression and Antidepressant Treatment , 2014, Nature Medicine.

[40]  P. Argani,et al.  Clear cell papillary renal cell carcinoma: micro-RNA expression profiling and comparison with clear cell renal cell carcinoma and papillary renal cell carcinoma. , 2014, Human pathology.

[41]  Jun Yu,et al.  Identification of microRNA-135b in Stool as a Potential Noninvasive Biomarker for Colorectal Cancer and Adenoma , 2014, Clinical Cancer Research.

[42]  M. Gariboldi,et al.  Circulating miR-378 in plasma: a reliable, haemolysis-independent biomarker for colorectal cancer , 2014, British Journal of Cancer.

[43]  L. Du,et al.  Down-regulation of miR-24-3p in colorectal cancer is associated with malignant behavior , 2014, Medical Oncology.

[44]  M. Leeflang,et al.  Cochrane diagnostic test accuracy reviews , 2013, Systematic Reviews.

[45]  K. Ramana,et al.  Aldose reductase inhibition suppresses colon cancer cell viability by modulating microRNA-21 mediated programmed cell death 4 (PDCD4) expression. , 2013, European journal of cancer.

[46]  T. Luedde,et al.  U6 is unsuitable for normalization of serum miRNA levels in patients with sepsis or liver fibrosis , 2013, Experimental & Molecular Medicine.

[47]  Yoshiyuki Yamamoto,et al.  Fecal miR-106a Is a Useful Marker for Colorectal Cancer Patients with False-Negative Results in Immunochemical Fecal Occult Blood Test , 2013, Cancer Epidemiology, Biomarkers & Prevention.

[48]  H. Miyajima,et al.  Mo1179 Potential Usefulness of Fecal Immunochemical Test Plus Fecal MicroRNA Assay As a Marker for Colorectal Cancer Screening , 2013 .

[49]  S. Mayor.  One in four cases of bowel cancer in England are diagnosed only after emergency admission , 2012, British medical journal.

[50]  H. Miyajima,et al.  Tu1191 Fecal MicroRNA Assays as a Marker for Colorectal Cancer Screening , 2012 .

[51]  Wen-Tsung Huang,et al.  MicroRNA-21-mediated regulation of Sprouty2 protein expression enhances the cytotoxic effect of 5-fluorouracil and metformin in colon cancer cells. , 2012, International journal of molecular medicine.

[52]  E. Mohammadi,et al.  Barriers and facilitators related to the implementation of a physiological track and trigger system: A systematic review of the qualitative evidence , 2017, International journal for quality in health care : journal of the International Society for Quality in Health Care.

[53]  C. von Wagner,et al.  Outcomes of the Bowel Cancer Screening Programme (BCSP) in England after the first 1 million tests , 2010, Gut.

[54]  Susan Mallett,et al.  QUADAS-2: A Revised Tool for the Quality Assessment of Diagnostic Accuracy Studies , 2011, Annals of Internal Medicine.

[55]  Yi Zheng,et al.  miR‐21 targets the tumor suppressor RhoB and regulates proliferation, invasion and apoptosis in colorectal cancer cells , 2011, FEBS letters.

[56]  Jun Yu,et al.  Detection of miR-92a and miR-21 in stool samples as potential screening biomarkers for colorectal cancer and polyps , 2011, Gut.

[57]  G. Federici,et al.  Differential expression of miR-144* as a novel fecal-based diagnostic marker for colorectal cancer , 2011, Journal of Gastroenterology.

[58]  A. Jemal,et al.  Global Cancer Statistics , 2011 .

[59]  D. Moher,et al.  Nonalcoholic Fatty Liver Disease and Acute Ischemic Stroke , 2010 .

[60]  H. Baba,et al.  MicroRNA Expression Profiling of Exfoliated Colonocytes Isolated from Feces for Colorectal Cancer Screening , 2010, Cancer Prevention Research.

[61]  D. Moher,et al.  Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. , 2010, International journal of surgery.

[62]  D. Banerjee,et al.  MiR-24 Tumor Suppressor Activity Is Regulated Independent of p53 and through a Target Site Polymorphism , 2009, PloS one.

[63]  S. Halloran.  Bowel cancer screening , 2009 .

[64]  D. Moher,et al.  Preferred reporting items for systematic reviews and meta-analyses: the PRISMA Statement , 2009, BMJ : British Medical Journal.

[65]  D. Moher,et al.  Preferred Reporting Items for Systematic Reviews and Meta-Analyses: The PRISMA Statement , 2009, BMJ : British Medical Journal.

[66]  Lianbo Yu,et al.  Detection of microRNA Expression in Human Peripheral Blood Microvesicles , 2008, PloS one.

[67]  Daniel B. Martin,et al.  Circulating microRNAs as stable blood-based markers for cancer detection , 2008, Proceedings of the National Academy of Sciences.

[68]  F. Slack,et al.  Oncomirs — microRNAs with a role in cancer , 2006, Nature Reviews Cancer.

[69]  Johannes B Reitsma,et al.  Bivariate analysis of sensitivity and specificity produces informative summary measures in diagnostic reviews. , 2005, Journal of clinical epidemiology.

[70]  Kenneth F Schulz,et al.  Refining clinical diagnosis with likelihood ratios , 2005, The Lancet.

[71]  Thanos Athanasiou,et al.  Summary receiver operating characteristic curve analysis techniques in the evaluation of diagnostic tests. , 2005, The Annals of thoracic surgery.

[72]  N. Arber,et al.  Fecal occult blood test for colorectal cancer screening. , 2002, Annals of oncology : official journal of the European Society for Medical Oncology.

[73]  R Wender,et al.  American Cancer Society Guidelines for the Early Detection of Cancer: Update of Early Detection Guidelines for Prostate, Colorectal, and Endometrial Cancers: ALSO: Update 2001—Testing for Early Lung Cancer Detection , 2001, CA: a cancer journal for clinicians.

[74]  A. Jemal,et al.  Global cancer statistics , 2011, CA: a cancer journal for clinicians.

[75]  R. Fletcher.  Should all people over the age of 50 have regular fecal occult-blood tests? Postpone population screening until problems are solved. , 1998 .

[76]  R. Fletcher.  Should all people over the age of 50 have regular fecal occult-blood tests? If it works, why not do it? , 1998, The New England journal of medicine.

[77]  J. B. Simon.  Should all people over the age of 50 have regular fecal occult-blood tests? Postpone population screening until problems are solved. , 1998, New England Journal of Medicine.

[78]  N. Laird,et al.  Meta-analysis in clinical trials. , 1986, Controlled clinical trials.

[79]  P. Dineen,et al.  Now and in the future. , 1970, AORN journal.